Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Gains from Investment Securities for 15 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 96.17% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Dec 2025, down 96.22%, and an annual FY2025 reading of $2.0 million, down 96.19% over the prior year.
  • Gains from Investment Securities was $2.0 million for Q4 2025 at Catalyst Pharmaceuticals, down from $53.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $53.0 million in Q4 2024 and bottomed at -$76000.0 in Q1 2021.
  • Average Gains from Investment Securities over 5 years is $7.8 million, with a median of $453000.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities tumbled 202.7% in 2021, then surged 26351.15% in 2024.
  • Year by year, Gains from Investment Securities stood at $136000.0 in 2021, then soared by 22781.62% to $31.1 million in 2022, then crashed by 98.54% to $453000.0 in 2023, then surged by 11605.52% to $53.0 million in 2024, then plummeted by 96.17% to $2.0 million in 2025.
  • Business Quant data shows Gains from Investment Securities for CPRX at $2.0 million in Q4 2025, $53.0 million in Q4 2024, and $13.8 million in Q2 2024.